The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel

Journal of Endocrinological Investigation

Volumn 34, Issue 9, 2011, Pages 692-697

  Bianchi, A ^a   De Marinis, L ^a   Fusco, A ^a   Lugli, F ^a   Tartaglione, L ^a   Milardi, D ^a   Mormando, M ^a   Lassandro, A P ^a   Paragliola, R ^a   Rota, C A ^a   Delia Casa, S ^a   Corsello, S M ^a   Brizi, M G ^b   Pontecorvi, A ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Lanreotide; Neuroendocrine tumors; Somatostatin analogues

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN A; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; GALLSTONE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; MALE; METASTASIS; METASTATIC WELL DIFFERENTIATED NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; OBSERVATIONAL STUDY; RESPONSE EVALUATION CRITERION IN SOLID TUMOR; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; GELS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856198509     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8058     Document Type: Article

References (35)

1. Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 (Suppl): v223-7.
2. Oberg K, Hellman P, Kwekkeboom D, Jelic S; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21 (Suppl): v220-2.
3. Boudreaux JP. Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS). Endocrinol Metab Clin North Am 2011, 40: 163-71.
4. Joseph S, Wang YZ, Boudreaux JP, et al. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin North Am 2011, 40: 205-31.
5. Steinmüller T, Kianmanesh R, Falconi M, et al.; Frascati Consensus Conference participants. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87: 47-62. (Pubitemid 350308294)
6. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009, 90: 209-13.
7. Eriksson B, Annibale B, Bajetta E, et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009, 90: 214-9.
8. Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011, 16: 286-95.
9. Saltz L, Trochanowski B, Buckley M, et al.Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993, 72: 244-8. (Pubitemid 23182080)
10. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996, 38: 430-8.
11. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996, 77: 402-8. (Pubitemid 26023360)
12. Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011, 30 (Suppl): 9-17.
13. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003, 17: 437-44. (Pubitemid 36259407)
14. Wymenga AN, Eriksson B, Salmela Pl, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-related symptoms. J Clin Oncol 1999, 17: 1111.
15. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139: 742-53.
16. Clements D, Elias E. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet 1985, 1: 874-5. (Pubitemid 15115142)
17. Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol (Oxf) 2000, 53: 755-8. (Pubitemid 32096687)
18. Shepherd JJ, Senator GB. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986, 2: 574. (Pubitemid 16054656)
19. Granberg D, Jacobsson H, Oberg K, Gustavsson J, Lehtihet M. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion 2008, 77: 92-5. (Pubitemid 351556386)
20. Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27: 4656-63.
21. Castellano D, Salazar R, Raymond E. Future perspectives on neuroendocrine tumors. Cancer Metastasis Rev 2011, 30 (Suppl): 35-40.
22. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effects. Ann Oncol 1997, 8: 1041-4. (Pubitemid 27475737)
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45: 228-47.
24. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of tumours of the digestive system. Lyon: IARC Press, 2010.
25. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
26. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 2006, 107: 2474-81. (Pubitemid 44748532)
27. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008, 6: 820-7.
28. Ducreux M, Ruszniewski P, Chayvialle JA, et al.The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000, 95: 3276-81.
29. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004, 80: 244-51. (Pubitemid 40187010)
30. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001, 37: 1014-9. (Pubitemid 32397687)
31. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002, 79: 180-7.
32. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol 2005, 11: 2041-4. (Pubitemid 40521010)
33. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009, 161: 331-8.
34. Wuster C, Both S, Cordes U, Omran W, Reisch R. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 2010, 4: 85.
35. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004, 151: 107-12. (Pubitemid 39117371)